Discover five myopia companies racing to go beyond glasses, as myopia is set to affect half the world by 2050.

Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

Learn when TIDE-based Sanger sequencing can replace NGS for measuring on-target gene editing efficiency in regulated ...

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer, as Hansoh Pharma and Medilink bring momentum with ...

Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...

Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science ...

Three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy ...

Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by ...

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

Two different antibody-drug conjugates (ADCs) targeting the same protein produced remarkably similar phase 3 results in relapsed small-cell lung cancer (SCLC) at WCLC 2026. Hansoh Pharma’s risvutatug ...

Research in the field of inflammatory diseases has become one of the hottest areas of drug development, spurred on by an interest in novel therapies that have the potential to be more precise and more ...